Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response.
Sheedy FJ, Sheedy FJ. · 2015
Read Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response. by Sheedy FJ, Sheedy FJ. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4310327.txt.
Introduction
Frederick J. Sheedy reviews miR-21, a tiny RNA that acts as a brake on inflammation. The review appeared in Frontiers in Immunology in 2015, and Sheedy writes as sole author. MiR-21 is among the most abundant microRNAs in many cell types, and the same signals that start inflammation also switch it on.
Recent work shows miR-21 then helps end the response: it dampens pro-inflammatory programs, above all in macrophages, the immune cells that drive much of the fire. That timing makes it a key switch between attack and resolution. Blocking it could stir inflammation where that helps, such as against tumors, while boosting it could calm harmful inflammation. The review maps the evidence and the therapeutic stakes.
Catalog record
| CREATOR | Sheedy FJ, Sheedy FJ. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response By Frederick J. Sheedy Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2015.00019 ABSTRACT miR-21 is one of the most highly expressed members of the small non-coding microRNA family in many mammalian cell types. Its expression is further enhanced in many diseased states including solid tumors, cardiac injury, and inflamed tissue. While the induction of miR-21 by inflammatory stimuli cells has been well documented in both hematopoietic cells of the immune system (particularly monocytes/macrophages but also dendritic and T-cells) and non-hematopoietic tumorigenic cells, the exact functional outcome of this elevated miR-21 is less obvious. Recent studies have confirmed a key role for miR-21 in the resolution of inflammation and in negatively regulating the pro-inflammatory response induced by many of the same stimuli that trigger miR-21 induction itself. In particular, miR-21 has emerged as a key mediator of the anti-inflammatory response in macrophages. This suggests that miR-21 inhibition in leukocytes will promote inflammation and may enhance current therapies for defective immune responses such as cancer, mycobacterial vaccines, or Th2-associated allergic inflammation. At the same time, miR-21 has been shown to promote inflammatory mediators in non-hematopoietic cells resulting in neoplastic transformation. This review will focus on functional studies of miR-21 during inflammation, which is complicated by the numerous molecular targets and processes that have emerged as miR-21 sensitive. It may be that the exact functional outcome of miR-21 is determined by multiple features including the cell type affected, the inducing signal, the transcriptomic profile of the cell, which ultimately affect the availability and ability to engage different target mRNAs and bring about its unique responses. Reviewing this data may illustrate that RNA-based oligonucleotide therapies for different diseases based upon miR-21 may have to target the unique and operative miRNA:mRNA interactions’ functionally active in disease. INTRODUCTION Micro-RNA-21 (miR-21) is an abundantly expressed microRNA in mammalian cells of multiple types (1–3). Its up-regulation is associated with many cancers, including those derived from both solid tissue (4, 5) and leukemic origin (6–9). The generation of a conditional miR-21 “knock-in” mouse confirmed that it functions as an oncogene with its overexpression resulting in malignant B-cell lymphoma (10). Functional studies performed in epithelia-, hepatocyte-, and glial cell-derived cell lines confirm that miR-21 regulates processes connected to cell growth, migration, and invasion (11–16), providing a mechanism for miR-21-mediated transformation of somatic cells. However, miR-21 is also expressed in hematopoietic cells of the immune system including B/T-cells, monocytes, macrophages, and dendritic cells (DCs). Activation of the immune system is strongly associated with tumor progression but also with surveying, responding to, and eliminating tumors as they arise. How increased miR-21 in these cell types facilitates tumor progression, as well as orchestrating the general immune response to pathogens and autoantigens in inflammatory disease, remains unclear. In this review, I will attempt to highlight some of the key findings on miR-21’s role in immunity and place this in the context of its dysregulation in disease including cancer and inflammation. I present a model of miR-21 as a key switch in immune circuits, controlling the balance between initial pro-inflammatory and later immuno-regulatory, anti-inflammatory responses, – dysregulation of which contributes to pathogenesis of inflammatory diseases including cancer and infection. MIR-21 EXPRESSION AND INDUCTION IN HEMATOPOIETIC CELLS Immune cell maturation Initial efforts to profile miRNA expression during hematopoiesis revealed that while miR-21 is moderately expressed in hematopoietic progenitors, its expression increases significantly as various cell types mature to an “active” state, including bone marrow-derived mast-cells (17), neutrophils (18), and activated T-cells of various lineages (19, 20). High miR-21 levels are therefore a marker of immune cell activation, although whether or not this reflects a cause or consequence of activation remained to be determined. It was found that miR-21 expression is RNA polymerase II-dependent and derived from a primary transcript that is both capped and polyadenylated (21). Similar to regular protein-coding mRNAs, miR-21 expression is dynamically regulated by complex signaling pathways and can be enhanced by extracellular signals during immune cell development. The myeloid precursor cell type, the monocyte, which can be differentiated into various mature cells depending upon the extracellular signals received, shows increased expression of miR-21 during activation. This was first demonstrated by the study of Kashashima et al. (22), where TPA (also known as PMA) was used to differentiate monocytes toward macrophages. Since then, studies showing treatment of monocytes with all-trans retinoic acid to generate neutrophils (18), GM-CSF/IL-4 treatment to generate immature DCs (23, 24), and treatment with LPS (a TLR4 specific mimetic of bacterial endotoxin) to generate activated macrophages (25, 26), as well as LPS-mediated B-cell activation (3), all revealed significant up-regulation of miR-21. Table 1 lists these examples alongside many other immunologically relevant examples, but their detailed discussion is beyond the scope of this review. However, taken together, these data confirm that miR-21 serves as an important marker of immune cell activation in multiple contexts. [Table: Select examples of miR-21 induction by inflammatory stimuli.] Turning the circuit “on” – induction of miR-21 by inflammatory stimuli Like regular Pol-II-regulated protein-coding mRNAs, which are regulated by a diverse array of signal-specific transcription factors that bind unique sites at the promoter region, miR-21 exhibits diversity in the signals, transcription factors, and proposed binding sites that regulate its expression in diverse contexts. Unlike, regular Pol-II-regulated protein coding-genes and like all miRNAs, miR-21 is subject to an additional layer of post-transcriptional regulation before the mature 20 nt bioactive form is generated. This involves processing of both the precursor and mature duplex miRNA from the primary miRNA transcript (pri-miR-21), carried out by the nuclear enzyme Drosha and its cytosolic counterpart, Dicer. Many of the induction studies of miR-21 by extracellular signals including TPA/PMA, LPS, IL-6, and TGF-β/BMP have shown it to be a later event in their respective signaling pathways (25, 27–29). Expression analysis downstream of oncogene Ras-induced signaling, which drives miR-21 through AP-1, has shown that the appearance of mature bioactive miR-21 is delayed relative to the generation of pri-miR-21 (33). Although a dearth of studies have defined the role of various transcription factors in the induction of miR-21, including NFκB in LPS-induced miR-21 (25, 30), AP-1 in PMA-mediated up-regulation (27), and STAT-3 for IL-6-induced miR-21 (28), the complexity of the predicted promoter region of pri-miR-21 (27, 28) and the occurrence of alternative transcription start sites (34) suggest that the regulation of miR-21 transcription is not straight forward. Several studies place miR-21 among the group of miRNAs whose post-transcriptional processing requires extra co-factors, notably the RNA helicase protein p68, which aids cleavage of the pri-miRNA transcript by Drosha (35). Although processing of mature miR-21 relative to other miRs may be differentially regulated by the inherent sequence differences of the miR-21 primary transcript recognized by Drosha/Dicer, a further layer of complexity is added when it is considered that the enzymes involved in miR-21 biogenesis are themselves regulated by extracellular signals, as shown in the study of TGF-β/BMP-mediated induction of mature miR-21. Here SMAD6, a key intracellular adapter protein activated by TGF-β signaling, bound to the primary miR-21 transcript and recruited p68 to promote Drosha-mediated cleavage during TGF-β signalling (29). Interestingly, in a study of miR-21 induction in a model of colon carcinoma epithelial–mesenchymal transition (EMT), combined